Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs

Question 611: What is the primary mechanism by which epinephrine reduces insulin secretion?

A. Predominantly through beta action
B. Through both alpha and beta actions
C. Through muscarinic receptors
D. Predominantly through alpha action (Correct Answer)

Explanation: ***Predominantly through alpha action*** - **Epinephrine** primarily reduces insulin secretion by stimulating **alpha-2 adrenergic receptors** on pancreatic beta cells. - Activation of these receptors leads to a decrease in **cAMP levels** and an inhibition of insulin release. *Predominantly through beta action* - **Beta-2 adrenergic receptor activation** on pancreatic beta cells typically **stimulates** insulin secretion, which is opposite to epinephrine's overall effect. - While epinephrine has both alpha and beta effects, the **alpha-2 inhibition** of insulin release predominates in this context. *Through both alpha and beta actions* - Although epinephrine exerts both alpha and beta effects, the **alpha-2 receptor-mediated inhibition** of insulin secretion is the dominant mechanism. - The **beta-2 receptor-mediated stimulation** of insulin release is overridden by the stronger inhibitory alpha-2 effect. *Through muscarinic receptors* - Muscarinic receptors are part of the **parasympathetic nervous system** and are involved in stimulating insulin secretion. - **Epinephrine** acts on adrenergic receptors, not muscarinic receptors, to influence insulin release.

Question 612: Which of the following is the MOST accurate statement about neostigmine?

A. It is a quaternary ammonium compound (Correct Answer)
B. It undergoes some metabolism in the liver, but its primary route of elimination is hydrolysis by plasma cholinesterases
C. It can cross the blood brain barrier
D. Prominent effect on cardiac muscle

Explanation: ***It is a quaternary ammonium compound*** - **Neostigmine** has a **quaternary ammonium group**, making it highly polar and **ionized** at physiological pH. - This chemical structure **limits its ability to cross lipid barriers** such as the blood-brain barrier [1].*It undergoes some metabolism in the liver, but its primary route of elimination is hydrolysis by plasma cholinesterases* - This description is more characteristic of **succinylcholine**, a depolarizing neuromuscular blocker, which is rapidly hydrolyzed by **plasma cholinesterase (pseudocholinesterase)** [2]. - **Neostigmine** is primarily eliminated by **renal excretion** and hepatic metabolism, not predominantly by plasma cholinesterases.*It can cross the blood brain barrier* - Due to its **quaternary ammonium structure**, neostigmine is **ionized** and **highly polar**, significantly impeding its passage across the **blood-brain barrier** [1]. - This characteristic explains why it primarily exerts its effects peripherally, rather than centrally.*Prominent effect on cardiac muscle* - While **cholinergic agonists** can have effects on the heart (e.g., bradycardia), **neostigmine's primary therapeutic action** is on **skeletal muscle** (to reverse neuromuscular blockade) and the **gastrointestinal tract** (to treat ileus). - Its effects on cardiac muscle are typically **less prominent** compared to its effects on other effector organs at therapeutic doses for its main indications.

Question 613: Which receptors mediate ganglionic transmission?

A. Presynaptic alpha-receptors
B. Postsynaptic beta-receptors
C. Postsynaptic dopaminergic receptors
D. Postsynaptic nicotinic receptors (Correct Answer)

Explanation: ***Postsynaptic nicotinic receptors*** - Ganglionic transmission in the **sympathetic** and **parasympathetic nervous systems** is primarily mediated by the binding of **acetylcholine** to **nicotinic acetylcholine receptors (nAChRs)** on the postsynaptic membrane of ganglia [3]. - These are **ligand-gated ion channels** [2] that, upon activation, cause rapid depolarization and excitation of the postganglionic neuron [1]. *Presynaptic alpha-receptors* - **Alpha-receptors** are typically found on adrenergic nerve terminals (presynaptic) or target organs (postsynaptic) and are involved in mediating the effects of **norepinephrine** and **epinephrine**, not the primary transmission at ganglia. - While presynaptic alpha-2 receptors can modulate neurotransmitter release, they do not mediate the primary excitatory ganglionic transmission itself. *Postsynaptic beta-receptors* - **Beta-receptors** are also **adrenergic receptors** (for norepinephrine and epinephrine) and are G-protein coupled receptors. - They are found on various target organs (e.g., heart, lungs) but are not the primary receptors responsible for direct ganglionic neurotransmission. *Postsynaptic dopaminergic receptors* - While **dopamine** can act as a neurotransmitter and modulate some ganglionic activity, **dopaminergic receptors** are not the primary receptors responsible for mediating the fast excitatory ganglionic transmission. - The main neurotransmitter at autonomic ganglia is **acetylcholine**, acting on nicotinic receptors [3].

Question 614: Anticholinesterases are ineffective in which of the following conditions?

A. Belladonna poisoning
B. Postoperative ileus
C. Cobra bite (Correct Answer)
D. Carbamate poisoning

Explanation: ***Cobra bite*** - Cobra venom contains **α-neurotoxins** (e.g., α-bungarotoxin) that cause **postsynaptic nicotinic receptor blockade** at the neuromuscular junction. - The toxin binds with **high affinity and essentially irreversibly** to nicotinic acetylcholine receptors, preventing acetylcholine from binding. - Anticholinesterases are **ineffective** because increasing acetylcholine concentration cannot displace the tightly bound neurotoxin from the receptors. - This represents a **non-competitive, irreversible blockade** that cannot be overcome by increasing substrate concentration. *Belladonna poisoning* - Caused by **antimuscarinic alkaloids** (atropine, scopolamine) that block muscarinic acetylcholine receptors. - Anticholinesterases would increase acetylcholine levels at muscarinic sites but cannot effectively reverse severe antimuscarinic toxicity. - Treatment is primarily **supportive** with physostigmine in selected cases, but this is not standard management. *Postoperative ileus* - Anticholinesterases like **neostigmine are effective** in treating postoperative ileus by increasing acetylcholine at muscarinic receptors in the GI tract. - This enhances **gastrointestinal motility** and is a therapeutic use of anticholinesterases. *Carbamate poisoning* - Carbamates are **reversible anticholinesterase inhibitors** causing cholinergic excess. - Additional anticholinesterases would be **contraindicated** (not ineffective) as they would worsen the acetylcholine accumulation. - Treatment involves **atropine** to block muscarinic effects, not more anticholinesterases.

Question 615: Methacholine acts primarily at which receptor?

A. M1
B. M2
C. M3 (Correct Answer)
D. M4

Explanation: ***M3*** - **Methacholine** is a non-selective muscarinic agonist that acts at all muscarinic receptors, but its **primary clinically relevant effects**, particularly in the airways (e.g., bronchoconstriction in asthma challenge tests), are mediated through **M3 receptors**. - **M3 receptors** are Gq-coupled and lead to **smooth muscle contraction**, glandular secretion, and vasodilation via nitric oxide release. *M1* - **M1 receptors** are primarily found in the central nervous system and autonomic ganglia, playing a role in **neuronal excitation** and **autonomic transmission**. - While methacholine can activate M1 receptors, this is not its predominant site of action for clinical uses. *M2* - **M2 receptors** are found in the heart and are Gi-coupled, leading to a **decrease in heart rate** and contractility. - While methacholine acts on M2 receptors, its most notable effects (like bronchoconstriction) are not primarily mediated through M2. *M4* - **M4 receptors** are primarily located in the central nervous system, where they modulate neurotransmitter release and contribute to **motor control** and cognition. - Methacholine has some affinity for M4, but it is not the primary receptor responsible for its clinically relevant effects.

Question 616: Exocytic release of acetylcholine is blocked by

A. Hemicholinium (inhibits choline reuptake)
B. Alphabungarotoxin (blocks ACh at receptors)
C. Vesamicol (interferes with ACh loading)
D. Botulinum toxin (blocks release of ACh) (Correct Answer)

Explanation: ***Botulinum toxin (blocks release of ACh)*** - **Botulinum toxin** acts by cleaving SNARE proteins (SNAP-25, synaptobrevin, syntaxin) which are essential for the fusion of synaptic vesicles with the presynaptic membrane, thereby **blocking exocytic release of acetylcholine**. - This blockage prevents the release of neurotransmitter from the nerve terminal, leading to muscle paralysis or reduced glandular secretions. *Hemicholinium (inhibits choline reuptake)* - **Hemicholinium** inhibits the high-affinity reuptake of **choline** into the presynaptic neuron, which is a crucial step in the synthesis of acetylcholine. - While it depletes acetylcholine stores over time, it does not directly block the immediate exocytic release of already synthesized acetylcholine. *Alphabungarotoxin (blocks ACh at receptors)* - **Alpha-bungarotoxin** is a potent antagonist that binds irreversibly and competitively to **nicotinic acetylcholine receptors (nAChR)** on the postsynaptic membrane. - Its action is postsynaptic, meaning it blocks the effect of acetylcholine once released, rather than preventing its release from the presynaptic terminal. *Vesamicol (interferes with ACh loading)* - **Vesamicol** inhibits the **vesicular acetylcholine transporter (VAChT)**, which is responsible for loading newly synthesized acetylcholine into synaptic vesicles. - By preventing the packaging of acetylcholine into vesicles, vesamicol reduces the amount of neurotransmitter available for release, but it does not directly block the exocytosis mechanism itself.

Question 617: Ocular effects that include mydriasis are characteristic of which of the following drugs?

A. phenylephrine (alpha agonist) (Correct Answer)
B. neostigmine (cholinesterase inhibitor)
C. phentolamine (alpha blocker)
D. mecamylamine (ganglionic blocker)

Explanation: ***phenylephrine (alpha agonist)*** - **Phenylephrine** is a direct-acting **alpha-1 adrenergic agonist** that causes contraction of the **pupillary dilator muscle**, leading to **mydriasis** (pupil dilation). [1] - It is frequently used clinically to dilate pupils for **ophthalmologic examinations** due to its selective action on alpha-1 receptors in the eye. [2] *neostigmine (cholinesterase inhibitor)* - **Neostigmine** inhibits acetylcholinesterase, increasing acetylcholine at the neuromuscular junction and muscarinic receptors. This leads to **miosis** (pupil constriction), not mydriasis. - Its ophthalmic use is primarily for treating **glaucoma** by improving aqueous humor outflow through cholinergic effects on the ciliary muscle. *phentolamine (alpha blocker)* - **Phentolamine** is a **non-selective alpha-adrenergic antagonist** that blocks both alpha-1 and alpha-2 receptors. - Alpha-1 receptor blockade in the eye would relax the pupillary dilator muscle, leading to **miosis** or prevention of mydriasis, not its induction. *mecamylamine (ganglionic blocker)* - **Mecamylamine** is a **ganglionic blocker** that antagonizes nicotinic receptors in both sympathetic and parasympathetic ganglia. - Blocking parasympathetic ganglia can cause some mydriasis, but ganglionic blockers have widespread, non-selective autonomic effects and are not primarily used for isolated mydriasis.

Question 618: The α2 agonist used in glaucoma is:

A. Brimonidine (Correct Answer)
B. Guanabenz
C. Guanfacine
D. Tizanidine

Explanation: ***Correct: Brimonidine*** - **Brimonidine** is an **α2-adrenergic agonist** commonly used in the treatment of glaucoma - It works by reducing **aqueous humor production** and increasing **uveoscleral outflow**, thereby lowering intraocular pressure - Available as eye drops (0.1%, 0.15%, 0.2% concentrations) *Incorrect: Guanfacine* - **Guanfacine** is an **α2A-adrenergic agonist** primarily used to treat **attention deficit hyperactivity disorder (ADHD)** and **hypertension** - It does not have a primary role in glaucoma treatment *Incorrect: Guanabenz* - **Guanabenz** is an **α2-adrenergic agonist** that acts centrally to reduce **sympathetic outflow**, used mainly as an **antihypertensive agent** - It is not indicated for the treatment of glaucoma *Incorrect: Tizanidine* - **Tizanidine** is an **α2-adrenergic agonist** primarily used as a **muscle relaxant** to manage spasticity - It is not used for glaucoma

Question 619: In an animal model, the phenomenon of vasomotor reversal of Dale can be demonstrated by which of the following?

A. Stimulation of alpha-1 followed by stimulation of beta-2
B. Stimulation of alpha-1 followed by block of beta-2
C. Stimulation of beta-1 receptor followed by block of beta-2 receptor
D. Blocking alpha-1 followed by stimulation of beta-2 (Correct Answer)

Explanation: ***Blocking alpha-1 followed by stimulation of beta-2*** - **Dale's vasomotor reversal** occurs when the typical pressor response to epinephrine is converted to a depressor (vasodilator) response. This phenomenon is demonstrated by first blocking **alpha-1 adrenergic receptors** (e.g., with phenoxybenzamine or phentolamine), and then administering **epinephrine**. - With alpha-1 receptors blocked, epinephrine cannot cause vasoconstriction. Instead, its stimulation of **beta-2 receptors** is unmasked, leading to vasodilation and a drop in blood pressure—the opposite of the usual pressor response. - This is the classic demonstration of Dale's vasomotor reversal in animal models. *Stimulation of alpha-1 followed by stimulation of beta-2* - Simultaneous stimulation of **alpha-1** and **beta-2 receptors** (as occurs with endogenous epinephrine without any blockade) typically results in a net **vasoconstrictor effect** due to the dominance of alpha-1 signaling in most vascular beds. - This scenario represents the normal response to epinephrine, not a reversal phenomenon. *Stimulation of alpha-1 followed by block of beta-2* - Stimulating **alpha-1 receptors** while blocking **beta-2 receptors** would enhance **vasoconstriction**, as the vasodilatory effects of beta-2 activation would be removed. - This would intensify the normal pressor effect, which is opposite to Dale's reversal. *Stimulation of beta-1 receptor followed by block of beta-2 receptor* - Stimulation of **beta-1 receptors** primarily affects the heart (increasing heart rate and contractility), while blocking **beta-2 receptors** would remove peripheral vasodilation. - Neither action directly relates to the **vasomotor reversal phenomenon**, which specifically involves reversing the vascular response to adrenergic agonists from vasoconstriction to vasodilation.

Question 620: Alpha-1a adrenergic blocker giving symptomatic relief in benign prostatic hyperplasia (BPH) is:

A. Tamsulosin (Correct Answer)
B. Tolazoline
C. Doxazosin
D. Prazosin

Explanation: ***Tamsulosin*** - **Tamsulosin** is a **uroselective alpha-1a adrenergic blocker** primarily targeting alpha-1a receptors in the prostate and bladder neck, causing relaxation of smooth muscle and improving urine flow with minimal impact on blood pressure. - This selectivity makes it highly effective for **symptomatic relief of BPH** with a lower risk of orthostatic hypotension compared to non-selective alpha-blockers. *Doxazosin* - **Doxazosin** is a **non-selective alpha-1 adrenergic blocker** that acts on alpha-1 receptors in both the prostate and peripheral vasculature. - While effective for BPH, its non-selectivity leads to a higher incidence of **orthostatic hypotension** and dizziness compared to tamsulosin, as it also lowers blood pressure significantly. *Tolazoline* - **Tolazoline** is a **non-selective alpha-adrenergic antagonist**, primarily used as a vasodilator to treat pulmonary hypertension and peripheral vascular disease. - It is not indicated for the treatment of BPH and has a different pharmacological profile and significant side effects unrelated to prostatic smooth muscle relaxation. *Prazosin* - **Prazosin** is a **non-selective alpha-1 adrenergic blocker** used to treat hypertension and, off-label, for BPH, but it has a short half-life requiring multiple daily doses. - Similar to doxazosin, its non-selective action on vascular smooth muscle can cause significant **first-dose syncope** and orthostatic hypotension, making it less favorable for BPH treatment compared to uroselective agents.

Practice by Chapter

Cholinergic Agonists

Practice Questions

Cholinergic Antagonists

Practice Questions

Adrenergic Agonists

Practice Questions

Adrenergic Antagonists

Practice Questions

Ganglionic Agents

Practice Questions

Neuromuscular Blocking Agents

Practice Questions

Autonomic Drugs in Ophthalmology

Practice Questions

Autonomic Drugs in Cardiovascular Disease

Practice Questions

Autonomic Drugs in Respiratory Disease

Practice Questions

Autonomic Drugs in Urological Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free